2例糖皮质激素药物致高血压的药学监护

doi:10.19803/j.1672-8629.20240283

中国药物警戒 ›› 2024, Vol. 21 ›› Issue (11): 1303-1305.
DOI: 10.19803/j.1672-8629.20240283

2例糖皮质激素药物致高血压的药学监护

刘鑫¹, 王国俊^2,*

¹泸州市中医医院药学部,四川泸州 646000;
²西南医科大学附属医院药学部,四川泸州 646000

收稿日期:2024-04-30 出版日期:2024-11-15 发布日期:2024-11-20
通讯作者: ^*王国俊,女,硕士,主任药师,临床药学。
作者简介:刘鑫,男,本科,药师,临床药学。

Pharmacological Care of Hypertension Due to Glucocorticoid Drugs

LIU Xin¹, WANG Guojun^2,*

¹Luzhou Traditional Chinese Medicine Hospital, Luzhou Sichuan 646000, China;
²The Affiliated Hospital of Southwest Medical University, Luzhou Sichuan 646000, China

Received:2024-04-30 Online:2024-11-15 Published:2024-11-20

摘要/Abstract

摘要： 目的探讨糖皮质激素药物致高血压的药学监护要点及临床药师发挥的作用。方法临床药师通过对2例使用糖皮质激素药物发生药源性高血压的患者进行药学监护,探讨其监护要点、临床处理措施及成效。结果与结论 临床药师通过有效开展药源性高血压患者的药学监护,能有效协助临床医师进行临床合理用药,确保用药安全。

关键词: 临床药师, 药学监护, 糖皮质激素, 药源性高血压, 临床处理, 临床合理用药

Abstract: Objective To investigate the priorities of pharmacological care of patients with hypertension due to glucocorticoid drugs and the effectiveness of pharmacists’ intervention. Methods Clinical pharmacists explored the key to such care, clinical management measures and effectiveness of pharmacological care of two patients who developed pharmacogenetic hypertension after using glucocorticoid medications. Results and conclusion Clinical pharmacists can effectively assist clinicians in the rational use of clinical medications to ensure safety by providing effective pharmacological care for patients with pharmacogenetic hypertension.

Key words: Clinical Pharmacist, Pharmacological Care, Glucocorticoid, Pharmacogenic Hypertension, Clinical Management, Rational Use of Clinical Medication

中图分类号:

刘鑫, 王国俊. 2例糖皮质激素药物致高血压的药学监护[J]. 中国药物警戒, 2024, 21(11): 1303-1305.

LIU Xin, WANG Guojun. Pharmacological Care of Hypertension Due to Glucocorticoid Drugs[J]. Chinese Journal of Pharmacovigilance, 2024, 21(11): 1303-1305.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20240283

https://zgywjj.magtechjournal.com/CN/Y2024/V21/I11/1303

参考文献

[1] CAI BQ, YAN XX, et al.Expert Consensus on Acute Exacerbation of Chronic Obstructive Pulmonary Disease in the People’s Republic of China(2023 Revised Edition)[J]. Int J Respir, 2023, 43(2): 132-149.
[2] ELLIOTT WJ.Drug interactions and Drugs that Affect Blood Pressure[J]. J Clin Hypertens (Greenwich), 2006, 8(10): 731-737.
[3] SARATHY H, SALMAN LA, LEE C, et al.Evaluation and Management of Secondary Hypertension[J]. Med Clin North Am, 2022, 106(2): 269-283.
[4] SUNDERRAM J, ANDROULAKIS IP.Molecular Mechanisms of Chronic Intermittent Hypoxia and Hypertension[J]. Crit Rev Biomed Eng, 2012, 40(4): 265-278.
[5] NESTEROV V, BERTOG M, CANONICA J, et al.Critical Role of the Mineralocorticoid Receptor in Aldosterone-dependent and Aldosterone-independent Regulation of ENaC in the Distal Nephron[J]. Am J Physiol Renal Physiol, 2021, 321(3): F257-F268.
[6] GOODWIN JE, GELLER DS.Glucocorticoid-induced Hypertension[J]. Pediatr Nephrol, 2012, 27(7): 1059-1066.
[7] PRZYBYCIŃSKI J, DROŻDŻAL S, DOMAŃSKI L, et al. Role of Endothelial Glucocorticoid Receptor in the Pathogenesis of Kidney Diseases[J]. Int J Mol Sci, 2021, 22(24): 13295.
[8] VEROUTI S, HUMMLER E, VANDERRIELE PE.Role of Glucocorticoid Receptor Mutations in Hypertension and Adrenal Gland hyperplasia[J]. Pflugers Arch, 2022, 474(8): 829-840.
[9] POFI R, CARATTI G, RAY DW, et al.Treating the Side Effects of Exogenous Glucocorticoids; Can We Separate the Good from the Bad?[J]. Endocr Rev, 2023, 44(6): 975-1011.
[10] CHEN ZY, GE JB, HUANG K, et al.Consensus of Chinese Experts on Standardized Diagnosis and Treatment Under the Joint Management of“three highs”(2023)[J]. Chinese Video Journal of Cardiology(中华心血管病杂志), 2023, 6(1): 1-11.
[11] KUPCZYK D, BILSKI R, KOZAKIEWICZ M, et al.11β-HSD as a New target in Pharmacotherapy of Metabolic Diseases[J]. Int J Mol Sci, 2022, 23(16): 8984.

[1]	张彩霞, 周易, 谭璐, 陈文明, 柳阳, 游禹. 1例脓毒血症继发肺曲霉菌感染患者的药学监护[J]. 中国药物警戒, 2024, 21(9): 1064-1067.
[2]	严妍, 刘乃一, 乔玲, 张毅, 杨晨. 别嘌醇片诱导的超敏反应综合征致暴发性1型糖尿病1例分析[J]. 中国药物警戒, 2024, 21(9): 1068-1070.
[3]	张乾, 恽渊, 何恋. 1例利培酮致高泌乳素血症患者的药学监护[J]. 中国药物警戒, 2024, 21(8): 936-938.
[4]	林彦馨, 刘艳辉, 董婧, 姚佳晨, 李文艳. 1例伊立替康致结肠癌患者急性肝损伤的药学监护[J]. 中国药物警戒, 2024, 21(6): 693-696.
[5]	黎海燕, 杨忠旭, 刘跃昆, 王丽虹. 1例甲氨蝶呤治疗异位妊娠致严重不良反应患者的药学监护[J]. 中国药物警戒, 2024, 21(4): 454-456.
[6]	刘琦, 张玉凤, 罗皓, 李歆. 106例安罗替尼临床应用的合理性与安全性分析[J]. 中国药物警戒, 2024, 21(3): 329-334.
[7]	吉秋霞, 金剑, 章斌. 特瑞普利单抗免疫相关不良事件药学监护[J]. 中国药物警戒, 2024, 21(3): 346-348.
[8]	范凯凯, 王聪, 刘洪峰, 王西勇. 临床药师对某院丙氨酰谷氨酰胺注射液应用干预分析[J]. 中国药物警戒, 2024, 21(2): 181-184.
[9]	沈江华, 孔超, 潘福敏, 褚燕琦. 1例贝纳柯克斯体椎体骨髓炎患者的药学监护[J]. 中国药物警戒, 2024, 21(10): 1166-1168.
[10]	史香芬, 孙志勇, 张旭锋, 卢晓静, 杜书章, 张晓坚. 基于智能信息管理系统的门诊麻精药品全流程管理[J]. 中国药物警戒, 2023, 20(8): 899-903.
[11]	张夏兰, 袁静, 吴斌, 秦媛媛. 甲磺酸阿帕替尼在恶性肿瘤患者的用药特征分析[J]. 中国药物警戒, 2023, 20(8): 927-932.
[12]	王然, 李轶凡, 刘小艳, 冯欣. 1例妊娠期药物暴露风险的药学监护[J]. 中国药物警戒, 2023, 20(8): 933-934.
[13]	陈婕, 秦侃. 肠外营养个体化给药实践评价[J]. 中国药物警戒, 2023, 20(7): 812-816.
[14]	刘婧, 夏亮, 张世杰. 1例多元药物过敏急性胰腺炎患者行药物激发试验的药学监护[J]. 中国药物警戒, 2023, 20(7): 822-824.
[15]	杨岩, 周德喜, 吴欣俐, 薛淑雅, 丁海华, 张泉, 张云玲. 84例新型抗肿瘤药品不良反应报告分析[J]. 中国药物警戒, 2023, 20(3): 334-338.

2例糖皮质激素药物致高血压的药学监护

Pharmacological Care of Hypertension Due to Glucocorticoid Drugs

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics